Curanex Pharmaceuticals Inc is a US-based company operating in Pharmaceuticals industry. The company is headquartered in Jericho, New York. The company went IPO on 2025-08-26. Curanex Pharmaceuticals Inc is a developmental stage pharmaceutical company. The firm is engaged in discovering, developing, and commercializing botanical drugs to treat patients suffering from inflammatory diseases and to develop therapies that offer potential benefits to patients with unmet clinical needs in various fields, such as autoimmune diseases, metabolic diseases and viral infections. Its lead candidate, Phyto-N, is a botanical extract from a single plant with anti-inflammatory properties that act via multiple targets and mechanisms. Its drug development pipelines encompass six various therapeutic areas: ulcerative colitis, atopic dermatitis, COVID-19, diabetes, NAFLD, and gout. Phyto-N is being developed as an orally administered alternative for patients with moderate to severe ulcerative colitis, aiming to address limitations of current treatments. The firm's two botanical drugs include Veregen (sinecatechins) and Fulyzaq/Mytesi (crofelemer).
Follow-Up Questions
Curanex Pharmaceuticals Inc의 CEO는 누구입니까?
Mr. Jun Liu은 2024부터 회사에 합류한 Curanex Pharmaceuticals Inc의 President입니다.
CURX 주식의 가격 성능은 어떻습니까?
CURX의 현재 가격은 $0.604이며, 전 거래일에 increased 0.7% 하였습니다.
Curanex Pharmaceuticals Inc의 주요 사업 주제나 업종은 무엇입니까?
Curanex Pharmaceuticals Inc은 Pharmaceuticals 업종에 속하며, 해당 부문은 Health Care입니다
